Investigational New Drug-enabling studies to use genetically modified mesenchymal stromal cells in patients with critical limb ischemia.

Peripheral artery disease is a condition in which blood vessels, usually in the legs, become narrowed or blocked, reducing blood flow. In its most severe form, called critical limb ischemia, blood flow can become so poor that tissue starts to die, often leading to pain, non-healing wounds, and in serious cases, amputation. One promising treatment approach has been to use mesenchymal stromal cells (MSCs) — a type of cell known for its ability to support tissue repair and encourage the growth of new blood vessels. Unfortunately, when tested in clinical trials, MSC therapy alone hasn't consistently worked well enough to meet the treatment goals doctors were hoping for. To try to improve on this, the research team engineered a more powerful version of MSC therapy. They genetically modified the MSCs so that, in addition to their natural properties, they also produce extra amounts of a protein called VEGF-A165. VEGF is a well-known signal that tells the body to grow new blood vessels — exactly what's needed to restore circulation in a limb with blocked or damaged arteries. Before any new cell-and-gene therapy like this can be tested in people, it must go through a rigorous evaluation process, and the results must be submitted to the U.S. Food and Drug Administration (FDA) as part of an application to begin human trials. This paper reports the results of that required preclinical testing. In lab-based (in vitro) studies, the researchers thoroughly characterized their engineered cells — confirming the identity and consistency of their cell banks, analyzing which genes were active and which proteins the cells released, and running tests to measure how biologically potent the modified cells were. They then moved to animal studies, using mice with weakened immune systems (so the mice wouldn't reject the human cells). These studies helped determine the right dose of cells needed to be effective, using a well-established model for testing new blood vessel growth. The researchers also tracked how long the injected cells remained in the body, measured how much VEGF protein ended up circulating in the bloodstream, and ran safety (toxicology) studies specifically designed to check for any serious harmful side effects. Across all these studies, the modified MSC/VEGF cells appeared both safe and effective — supporting the idea that boosting MSCs with extra VEGF could meaningfully improve their ability to restore blood flow, compared to unmodified MSCs alone. Based on these encouraging results, the researchers have laid the groundwork to move this combined cell-and-gene therapy into its first human clinical trial. If successful, this approach could eventually offer a new treatment option for people with severe circulation problems in their limbs — potentially helping to prevent amputations and improve quality of life for a condition that currently has limited effective treatments.